Trastuzumab: tested with established drugs

68 studies: they are given beside it. Page 1 of 1. Open to participants first (7), then studies with results posted, then the rest; newest registration first within each.

• A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.RecruitingNCT07788196Phase 2Report a problem
• Clinical Trials Comparing Trastuzumab Plus Bevacizumab With Bevacizumab as First-line Maintenance Therapy for Epithelial Ovarian CancerRecruitingNCT07779538Phase 3Report a problem
• Trastuzumab Plus Chemotherapy vs Chemotherapy Alone in First-line HER2 Positive Advanced Biliary Tract Cancer PatientsRecruitingNCT07062263Phase 3Report a problem
• Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ PatientsRecruitingNCT06650332Phase 1/2Report a problem
• Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast CancerRecruitingNCT05800756Phase 2Report a problem
• Neoadjuvant Treatment With Palbociclib and Exemestane Plus Trastuzumab and Pyrotinib in Estrogen Receptor (ER)-Positive, HER2-positive Breast CancerNot yet recruitingNCT04858516Phase 2Report a problem
• Study of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in the Treatment of GC/EGCRecruitingNCT04819971Phase 2Report a problem
• Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant TherapyTerminatedNCT04578106Phase 2Results postedReport a problem
• Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast CancerActive, not recruitingNCT03879577Phase 2Results postedReport a problem
• Trial to Compare the Safety, Efficacy and Immunogenicity of TX05 With Herceptin® in HER2+ Early Breast CancerCompletedNCT03556358Phase 3Results postedReport a problem
• Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast CancerCompletedNCT03084237Phase 3Results postedReport a problem
• A Study Of PF-05280014 Or Trastuzumab Plus Taxotere® And Carboplatin In HER2 Positive Breast Cancer In The Neoadjuvant Setting (REFLECTIONS B327-04)CompletedNCT02187744Phase 3Results postedReport a problem
• A Study of Pertuzumab and Trastuzumab Subcutaneous (SC) Treatment in Combination With a Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Breast CancerCompletedNCT02019277Phase 3Results postedReport a problem
• A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast CancerCompletedNCT01998906Phase 3Results postedReport a problem
• A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)CompletedNCT01989676Phase 3Results postedReport a problem
• A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast CancerCompletedNCT01940497Phase 3Results postedReport a problem
• A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast CancerTerminatedNCT01928615Phase 2Results postedReport a problem
• Combination Chemotherapy in Treating Patients With Advanced Stomach, Gastroesophageal, or Esophageal CancerCompletedNCT01928290Phase 2Results postedReport a problem
• Efficacy and Safety Study of ABP 980 Compared With Trastuzumab in Women With HER2-positive Early Breast CancerCompletedNCT01901146Phase 3Results postedReport a problem
• Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor CellsTerminatedNCT01779050Phase 2Results postedReport a problem
• A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin TreatmentCompletedNCT01301729Phase 4Results postedReport a problem
• Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast CancerCompletedNCT01275677Phase 3Results postedReport a problem
• Demonstrate Efficacy and Safety of Metastatic Breast CancerCompletedNCT01084876Phase 3Results postedReport a problem
• Evaluate Safety, Efficacy and PharmacokineticsCompletedNCT01084863Phase 1/2Results postedReport a problem
• ToGA Study - A Study of Herceptin (Trastuzumab) in Combination With Chemotherapy Compared With Chemotherapy Alone in Patients With HER2-Positive Advanced Gastric CancerCompletedNCT01041404Phase 3Results postedReport a problem
• Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast CancerCompletedNCT00971737Phase 2Results postedReport a problem
• A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast CancerCompletedNCT00950300Phase 3Results postedReport a problem
• Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by SurgeryCompletedNCT00770809Phase 3Results postedReport a problem
• Lapatinib +/- Trastuzumab In Addition To Standard Neoadjuvant Breast Cancer Therapy.CompletedNCT00524303Phase 2Results postedReport a problem
• THOR Study: A Study of Continued Herceptin (Trastuzumab) in Combination With Second Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.CompletedNCT00448279Phase 3Results postedReport a problem
• A Study of Herceptin (Trastuzumab) in Combination With 2nd-Line Chemotherapy in Patients With HER2 Positive Metastatic Breast Cancer.CompletedNCT00444587Phase 2Results postedReport a problem
• Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer PatientsCompletedNCT00270894Phase 2Results postedReport a problem
• A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast CancerCompletedNCT00022672Phase 3Results postedReport a problem
• A Multicenter, Double-blind, Randomized, Parallel-group, Phase III Study of the Efficacy and Safety of QL1701 Plus Docetaxel Versus Herceptin® Plus Docetaxel as First Line Therapy in Patients With HER2-positive Metastatic Breast CancerCompletedNCT05629949Phase 3Report a problem
• Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal TumorsCompletedNCT05515796Phase 2Report a problem
• Neoadjuvant Ontruzant (SB3) in Patients With HER2-positive Early Breast Cancer: An Open-Label (NeoON)Status unknownNCT05036005Phase 4Report a problem
• Single-arm, Multi-center Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin-bound Paclitaxel and Trastuzumab in Neoadjuvant Treatment of Her2-positive Early or Locally Advanced Breast CancerStatus unknownNCT04917900Phase 2Report a problem
• Pyrotinib, Trastuzumab And Abraxane in HER2-positive MBC With Brain MetastasisStatus unknownNCT04639271Phase 2Report a problem
• Palbociclib, Trastuzumab,Pyrotinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER/PR Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in ChinaStatus unknownNCT04334330Phase 2Report a problem
• CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted TherapyActive, not recruitingNCT04266249Phase 2Report a problem
• A Study Of SIBP-01 Or CN-Trastuzumab Plus Docetaxel And Carboplatin In HER2 Positive Breast CancerCompletedNCT03989037Phase 3Report a problem
• Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.Status unknownNCT03947242Not applicableReport a problem
• Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Chemotherapy in Patients With HER2 Positive Breast CancerStatus unknownNCT03847818Not applicableReport a problem
• Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.CompletedNCT03735966Phase 2Report a problem
• Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor CancersTerminatedNCT03680560Phase 1Report a problem
• Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast CancerActive, not recruitingNCT03379428Phase 1/2Report a problem
• Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab in the Treatment of Siewert II ，III of Human Epidermal Growth Factor Receptor-2(HER-2) Positive Gastroesophageal Junction Adenocarcinoma： A Randomized, Controlled Clinical StudyStatus unknownNCT03368131Phase 2Report a problem
• Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Trastuzumab in HER2+ Breast Cancer PatientsStatus unknownNCT03144947Phase 2Report a problem
• A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer PatientsCompletedNCT03013504Phase 3Report a problem
• T- XELOX in HER2-positive Stage III Gastric Cancer After D2 GastrectomyStatus unknownNCT02250209Phase 2Report a problem
• Safety and QoL of Trastuzumab With Lapatinib or Chemiotherapy in MBC and HER2+ Patients Refractory to Anti HER2 TherapiesStatus unknownNCT02238509Phase 2Report a problem
• A Study to Investigate the Tolerability of Subcutaneous (SC) Trastuzumab Administration in Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Early Breast Cancer (eBC) Using Either a Single-Use Injection Device or Manual AdministrationCompletedNCT02194166Phase 3Report a problem
• A Study of Participant Satisfaction and Safety With Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast CancerCompletedNCT01964391Phase 3Report a problem
• Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial CarcinomaCompletedNCT01828736Phase 2Report a problem
• Elderly Metastatic Breast Cancer: Pertuzumab-Herceptin vs Pertuzumab-Herceptin-Metronomic Chemotherapy, Followed by T-DM1CompletedNCT01597414Phase 2Report a problem
• Lapatinib With Trastuzumab in Treating Patients With HER2-Negative/HER2 Mutant Metastatic Breast CancerWithdrawnNCT01557764Phase 2Report a problem
• Docetaxel, Carboplatin, and Trastuzumab and/or Lapatinib in Treating Women With Stage I, Stage II, or Stage III Breast Cancer That Can Be Removed by SurgeryCompletedNCT00769470Phase 2Report a problem
• Trastuzumab in Treating Women With HER2-Positive Early Breast CancerStatus unknownNCT00712140Phase 3Report a problem
• BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the BrainWithdrawnNCT00397501Phase 1/2Report a problem
• Liposomal Doxorubicin, Trastuzumab, and Docetaxel in HER2 Positive Metastatic Breast CancerTerminatedNCT00377780Phase 2Report a problem
• TBP Study With Capecitabine Plus Minus TrastuzumabCompletedNCT00148876Phase 3Report a problem
• Benefit of Adding Trastuzumab to Second Line Chemotherapy in Breast Cancer Patients Previously Treated With TrastuzumabTerminatedNCT00130507Phase 2Report a problem
• Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast CancerCompletedNCT00038402Phase 3Report a problem
• Chemotherapy With or Without Trastuzumab in Treating Patients With Metastatic OsteosarcomaCompletedNCT00023998Phase 2Report a problem
• Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast CancerCompletedNCT00006228Phase 2Report a problem
• Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2TerminatedNCT00004935Phase 3Report a problem
• Doxorubicin and Cyclophosphamide Plus Paclitaxel With or Without Trastuzumab in Treating Women With Node-Positive Breast Cancer That Overexpresses HER2CompletedNCT00004067Phase 3Report a problem
• Monoclonal Antibody Plus Chemotherapy in Treating Patients With Advanced Colorectal Cancer That Overexpresses HER2CompletedNCT00003995Phase 2Report a problem

← Trastuzumab